RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.comTrimira's Identafi 3000 Oral Cancer Screening Device Recognized in Modern Hygienist 2009 Top 30 Products
Identafi: First and Only Device With Multispectral Technology
HOUSTON, Dec. 8, 2009 — Trimira® LLC's award-winning Identafi® 3000 oral cancer detection device was named among 2009's Top 30 Products by the 70,000 readers of dental industry magazine Modern Hygienist (www.dprworld.com/mh).
Modern Hygienist's Top 30 Products are those products which have received the most response from readers and users based on web traffic in the magazine's product database and its digital reader service card. Modern Hygienist analyzes traffic on its comprehensive product database and compiles data with feedback from reader response cards to determine which products captured readers' attention in 2009.
Modern Hygienist is published by Chicago-based Advanstar Communications, Inc.
During 2009, Trimira introduced the updated Identafi® 3000 ultra, which is the latest version of the industry-leading oral cancer detection device. Created expressly for intraoral use, the small, cordless Identafi® 3000 ultra is ergonomically shaped for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians.
Identafi® 3000 ultra
www.trimira.net/identafiIdentafi® 3000 ultra incorporates triple-wavelength, or "multispectral," optical reflectance and fluorescence technology that represents a quantum leap in the visualization of oral cancer or premalignant dysplasia. Unlike other methods, Identafi® 3000 ultra empowers doctors and dentists to pinpoint biochemical and morphological changes in cells. Identafi® 3000 ultra's multispectral spectroscopy minimizes false positives and reveals abnormalities in oral tissue missed by the naked eye. Multispectral technology not only is effective in screening oral cancers but also in diagnosing cervical, skin, gastrointestinal, and bladder cancers.
About Trimira® LLC
Trimira® LLC is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira® sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm®, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm®'s core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit Trimira® at: http://www.trimira.net/
Animations
Identafi® Technology
Identafi® Process
Screening Results
Training
